Sunday, 26 May 2019

Cartherics and panCELLa announce collaborative agreement for cell therapy

15 February 2019 | News

panCELLa will integrate their FailSafeTMtechnology into Cartherics' proprietary homozygous HLA haplotype cells

image credit- drugsafetynews.com

image credit- drugsafetynews.com

Cartherics and panCELLa have announced their collaboration to research, develop and commercialize products for the treatment of cancer and other debilitating diseases using cell therapy.

Prof. Alan Trounson, CEO Cartherics said, "This technology is an important step to ensure the safety of the next generation of very effective gene-edited stem cell-derived immunotherapies.”

Dr. Andras Nagy, President and CSO of panCELLa said, "We anticipate that this partnership will provide for the highest level of cell therapy safety, stated.  "We are pleased to partner with Cartherics to address the needs of immunotherapy treated cancer patients and to generate FailSafeTM cells for cell therapies in regenerative medicine.  It is our mission to provide off-the-shelf universally safe cell therapies for all humankind."

panCELLa will integrate their FailSafeTMtechnology into Cartherics' proprietary homozygous HLA haplotype cells to bring the power of safe cell therapy to a greater number of patients.

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

 

Survey Box

Will stem cell therapy market witness highest growth in Asia by 2020?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls